1
|
Pignata S, Califano D, Lorusso D, Arenare L, Bartoletti M, De Giorgi U, Andreetta C, Pisano C, Scambia G, Lombardi D, Farolfi A, Cinieri S, Passarelli A, Salutari V, De Angelis C, Mignogna C, Priolo D, Capoluongo ED, Tamberi S, Scaglione GL, Arcangeli V, De Cecio R, Scognamiglio G, Greco F, Spina A, Turinetto M, Russo D, Carbone V, Casartelli C, Schettino C, Perrone F. MITO END-3: Efficacy of Avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy. Ann Oncol 2024:S0923-7534(24)00128-5. [PMID: 38704093 DOI: 10.1016/j.annonc.2024.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Revised: 02/28/2024] [Accepted: 04/25/2024] [Indexed: 05/06/2024] Open
Abstract
BACKGROUND Immunotherapy combined with chemotherapy significantly improves progression-free survival compared to first-line chemotherapy alone in advanced endometrial cancer, with a much larger effect size in microsatellite-instability high (MSI-H) cases. New biomarkers might help to select patients that may have benefit among those with a microsatellite-stable (MSS) tumor. METHODS In a pre-planned translational analysis of the MITO END-3 trial, we assessed the significance of genomic abnormalities in patients randomized to standard carboplatin/paclitaxel without or with avelumab. RESULTS Out of 125 randomized patients, 109 had samples eligible for next-generation sequencing (NGS) analysis, and 102 had MSI tested. According to The Cancer Genome Atlas (TCGA), there were 29 cases MSI-H, 26 MSS TP53 wild-type (wt), 47 MSS TP53 mutated (mut), and one case with POLE mutation. Four mutated genes were present in more than 30% of cases: TP53, PIK3CA, ARID1A, and PTEN. Eleven patients (10%) had a BRCA1/2 mutation (five in MSI-H and six in MSS). High TMB (≥10 Muts/Mb) was observed in all MSI-H patients, in four out of 47 MSS/TP53 mut, and no case in the MSS/TP53 wt category. The effect of avelumab on progression-free survival significantly varied according to TCGA categories, being favorable in MSI-H and worst in MSS/TP53 mut (P interaction=0.003); a similar non-significant trend was seen in survival analysis. ARID1A and PTEN also showed a statistically significant interaction with treatment effect, which was better in the presence of the mutation (ARID1A P interaction=0.01; PTEN P interaction=0.002). CONCLUSION The MITO END-3 trial results suggest that TP53 mutation is associated with a poor effect of avelumab, while mutations of PTEN and ARID1A are related to a positive effect of the drug in patients with advanced endometrial cancer.
Collapse
Affiliation(s)
- S Pignata
- Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy.
| | - D Califano
- Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy
| | - D Lorusso
- Gynecologic Oncology Unit, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome, Italy; Catholic University of Sacred Heart, Rome, Italy
| | - L Arenare
- Clinical Trial Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy
| | - M Bartoletti
- Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081 (PN), Italy
| | - U De Giorgi
- Dipartimento Oncologico, IRCCS Istituto Romagnolo per lo studio dei Tumori (IRST Dino Amadori, Meldola (FC)
| | - C Andreetta
- Dipartimento di Oncologia - ASU FC S. Maria della Misericordia -Udine
| | - C Pisano
- Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy
| | - G Scambia
- Gynecologic Oncology Unit, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome, Italy; Catholic University of Sacred Heart, Rome, Italy
| | - D Lombardi
- Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano 33081 (PN), Italy
| | - A Farolfi
- Clinical and Experimental Oncology Unit, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, IRCCS, Meldola, Italy
| | - S Cinieri
- U.O.C. Oncologia Medica - Ospedale Senatore Antonio Perrino, Brindisi, Italy
| | - A Passarelli
- Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy
| | - V Salutari
- Gynecologic Oncology Unit, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome, Italy
| | - C De Angelis
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - C Mignogna
- Division of Anatomic Pathology and Cytopathology. Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples, Italy
| | - D Priolo
- Oncology Unit, S Vincenzo Hospital, Taormina, Italy
| | - E D Capoluongo
- Department of Molecular Medicine and Medical Biotechnology, Università degli Studi di Napoli Federico II, Naples, Italy; Azienda Ospedaliera per L'Emergenza, Cannizzaro, Catania, Italy
| | - S Tamberi
- Oncology Unit, Santa Maria hospital, Ravenna AUSL Romagna, Italy
| | - G L Scaglione
- Istituto Dermopatico Dell'Immacolata IDI-IRCSS, Rome, Italy
| | - V Arcangeli
- UO Oncologia - Ospedale degli Infermi Rimini (RN), Italy
| | - R De Cecio
- Division of Anatomic Pathology and Cytopathology. Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples, Italy
| | - G Scognamiglio
- Division of Anatomic Pathology and Cytopathology. Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples, Italy
| | - F Greco
- Medical Oncology Unit, AULSS 9 Regione Veneto, Scaligera - Ospedale Generale Mater Salutis, Legnago, Italy
| | - A Spina
- Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy
| | - M Turinetto
- Department of Oncology, University of Turin, Ordine Mauriziano Hospital, 10128 Turin, Italy
| | - D Russo
- Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy
| | - V Carbone
- Gynecologic Oncology Unit, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome, Italy
| | - C Casartelli
- Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy
| | - C Schettino
- Clinical Trial Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy
| | - F Perrone
- Clinical Trial Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy
| |
Collapse
|
2
|
Smith CP, Armstrong WR, Clark K, Moore J, Roberts M, Farolfi A, Reiter RE, Rettig M, Shen J, Valle L, Nickols NG, Steinberg ML, Czernin J, Kishan AU, Calais J. PSMA PET Guided Salvage Radiotherapy Among Prostate Cancer Patients in the Post-Prostatectomy Setting: A Single Center Post-Hoc Analysis. Int J Radiat Oncol Biol Phys 2023; 117:e438. [PMID: 37785423 DOI: 10.1016/j.ijrobp.2023.06.1612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) shows improved sensitivity and specificity for detection of locoregional and distant metastatic prostate cancer (PCa) compared to conventional imaging, especially at lower PSA levels as is often the case in the biochemically recurrent (BCR), post radical prostatectomy (RP) setting. Providers are now utilizing PSMA PET findings to guide their salvage radiotherapy (sRT) treatment fields and doses, although it is not well understood how PSMA PET guided sRT impacts patient outcomes. MATERIALS/METHODS This was a post-hoc analysis of 5 prospective studies of PSMA PET conducted at UCLA from 2016 to 2021 that included patients with recurrent PCa following RP. Patients were included in this retrospective study if they initiated sRT within 3 months of PSMA PET, had at least 12 months of follow up after sRT completion, had available sRT treatment details, and did not have distant metastases (DM) by conventional imaging on upfront staging. Patients treated with palliative RT were excluded. BCR following sRT was defined as an increase in PSA of 0.2 ng/ml above the post sRT nadir. Metastasis directed therapy (MDT) was defined as sRT to all PSMA+ N1 and M1 lesions. Baseline patient demographics, PSMA PET findings, sRT & ADT treatment details, and patient outcome data were collected. RESULTS A total of 176 patients were included in this study. Median time between RP and PSMA PET was 38 months (range 1-329). Median PSA at the time of the PSMA PET was 0.625 ng/mL (range 0.063-35). PSMA PET was positive in 128 patients (73%): 21 (12%) miT+N0M0, 55 (31%) miTxN1M0 and 52 (30%) miTxNxM1 with 19 (11%) miTxNxM1a, 31 (18%) miTxNxM1b, and 2 (1%) miTxNxM1c. Median number of lesions seen on positive PSMA scans was 1 (range 1-8). 39 (22%) patients were subsequently treated with sRT to the prostate bed (PB) only, 59 (34%) to PB + pelvic lymph nodes (PLNs), 33 (19%) to PLNs only, 7 (4%) to PB + PLNs + DM, 7 (4%) to PLNs + DM, and 31 (18%) to DM only. 59 (34%) patients were treated with concurrent ADT at a median duration of 6 months (range 1-39). At a median follow-up of 32 months (range 12-70) after sRT, 80 patients (45%) did not develop BCR or imaging relapse (IR) following sRT, 24 patients (14%) developed BCR but not IR, 1 patient (<1%) developed IR only, and 70 patients (40%) developed both BCR and IR. The median time to BCR and IR following sRT was 15 months (range 1-48) and 19 months (range 6-61), respectively. 1 year post sRT biochemical recurrence free survival was 77%. Of the 83 patients treated with MDT, 32 (39%) did not develop subsequent disease relapse. CONCLUSION This post hoc analysis assessed the outcomes of 176 patients treated with PSMA PET guided salvage RT, proving it to be an effective method for treating both pelvic and extrapelvic recurrent PCa. Further investigation is needed to assess the full extent of patient outcomes in this population.
Collapse
Affiliation(s)
- C P Smith
- Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
| | - W R Armstrong
- Ahmanson Translational Theranostics Division, UCLA Nuclear Medicine, Los Angeles, CA
| | - K Clark
- Ahmanson Translational Theranostics Division, Los Angeles, CA
| | - J Moore
- Ahmanson Translational Theranostics Division, UCLA Nuclear Medicine, Los Angeles, CA
| | - M Roberts
- Ahmanson Translational Theranostics Division, UCLA Nuclear Medicine, Los Angeles, CA
| | - A Farolfi
- Ahmanson Translational Theranostics Division, UCLA Nuclear Medicine, Los Angeles, CA
| | - R E Reiter
- Department of Urology, University of California, Los Angeles, Los Angeles, CA
| | - M Rettig
- Department of Medical Oncology, University of California, Los Angeles, Los Angeles, CA
| | - J Shen
- Department of Medical Oncology, University of California, Los Angeles, Los Angeles, CA
| | - L Valle
- Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
| | - N G Nickols
- Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
| | - M L Steinberg
- Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
| | - J Czernin
- Ahmanson Translational Theranostics Division, UCLA Nuclear Medicine, Los Angeles, CA
| | - A U Kishan
- Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
| | - J Calais
- Ahmanson Translational Theranostics Division, UCLA Nuclear Medicine, Los Angeles, CA
| |
Collapse
|
3
|
Djaïleb L, Armstrong W, Thompson D, Gafita A, Farolfi A, Grogan T, Fendler W, Czernin J, Hope T, Calais J. Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: Follow-up analysis of a multicenter prospective phase 3 imaging trial. Médecine Nucléaire 2023. [DOI: 10.1016/j.mednuc.2023.01.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
|
4
|
Gafita A, Djaileb L, Rauscher I, Fendler W, Hadaschik B, Herrmann K, Calais J, Czernin J, Rettig M, Eiber M, Weber M, Benz M, Farolfi A. Practical RECIP: Visual assessment of response evaluation criteria In PSMA-PET 1.0. Médecine Nucléaire 2023. [DOI: 10.1016/j.mednuc.2023.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
|
5
|
Farolfi A, Petracci E, Gurioli G, Tedaldi G, Casanova C, Arcangeli V, Rosati M, Burgio S, Cursano M, Lolli C, Schepisi G, De Giorgi U. 53P Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.100833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
|
6
|
Robesti D, Mazzone E, Gandaglia G, Stabile A, Necchi A, Raggi D, Marandino L, Cirulli G, Scuderi S, Barletta F, De Angelis M, Balestrazzi E, Fanti S, Cucchiara V, Farolfi A, Bianchi L, Schiavina R, Montorsi F, Briganti A. The prognostic role of 68Ga-PSMA PET/CT and the impact of metastasis-directed therapy on cancer progression in men with biochemical recurrence from prostate cancer. Results from a large, single Institution series. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)01159-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
7
|
Farolfi A, Scarpi E, Loizzi V, Cioffi R, Tuninetti V, Valabrega G, Godina C, Casanova C, Ventriglia J, Arezzo F, Pignata S, Candotti G, Cormio G, De Giorgi U. 23P Pre-treatment inflammatory indexes predict the clinical outcome of patients with endometrial cancer: A MITO24 study. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.100794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
|
8
|
Droghetti M, Bianchi L, Balestrazzi E, Ceci F, Costa F, Pissavini A, Presutti M, Scarlatti R, Farolfi A, Mei R, Castellucci P, Puliatti S, Gandaglia G, Larcher A, Mottrie A, Briganti A, Morganti A, Fanti S, Montorsi F, Schiavina R, Brunocilla E. PSMA-PET for recurrent prostate cancer and guidance of salvage treatments: Is the sooner always the better? (shoot blind or sharpshooting?). Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00312-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
9
|
Bianchi L, Pissavini A, Droghetti M, Pugliese M, Massimiliano P, Riccardo S, Balestrazzi E, Mei R, Farolfi A, Vetrone L, Serani F, Calderoni L, Stretta M, Morganti A, Schiavina R, Castellucci P, Fanti S, Brunocilla E. PSMA-PET in high-risk prostate cancer patients suitable for radical treatments: Scenario of detection and clinical impact for staging setting. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00118-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
10
|
Spohn S, Farolfi A, Schandeler S, Vogel M, Ruf J, Mix M, Kirste S, Ceci F, Fanti S, Lanzafame H, Gratzke C, Sigle A, Combs S, Bernhardt D, Gschwend J, Buchner J, Trapp C, Belka C, Bartenstein P, Eiber M, Nekolla S, Schiller K, Grosu A, Schmidt-Hegemann N, Zamboglou C, Peeken J. The Maximum Standardized Uptake Value in Patients with Recurrent or Persistent Prostate Cancer after Radical Prostatectomy and PSMA-PET-Guided Salvage Radiotherapy – A Multicenter Retrospective Analysis. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Bianchi L, Vetrone L, Mei R, Farolfi A, Giunchi F, De Giovanni A, Serani F, Costa F, Droghetti M, Pissavini A, Schiavina R, Brunocilla E, Castellucci P, Fanti S. Immunohistochemical PSMA expression and histology predictors in primary staging high-risk prostate cancer patients studied with PSMA PET/CT. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)02468-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
12
|
Robesti D, Mazzone E, Gandaglia G, Stabile A, Necchi A, Raggi D, Marandino L, Cirulli G, Scuderi S, Barletta F, De Angelis M, Balestrazzi E, Fanti S, Farolfi A, Bianchi L, Schiavina R, Montorsi F, Briganti A. When node-positive prostate cancer should be considered a systemic disease? assessing the prognostic role of preoperative 68Ga-PSMA PET/ CT results in patients with lymph node invasion at final pathology. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01280-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
13
|
Sorce G, Mazzone E, Stabile A, Robesti D, Bravi C, Scuderi S, Leni R, Balestrazzi E, Fanti S, Farolfi A, Bianchi L, Schiavina R, Montorsi F, Briganti A. Reliability of 68Ga-PSMA PET/CT in assessing real nodal burden in men with cN1 disease: clinical implications for patient counselling and multi-modal treatments. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)00996-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
14
|
Costa F, Bianchi L, Pissavini A, Droghetti M, Piazza P, Balestrazzi E, Chessa F, Ceci F, Mei R, Farolfi A, Puliatti S, Larcher A, Gandaglia G, Mottrie A, Bianchi A, Fanti S, Montorsi F, Schiavina R, Brunocilla E. The impact of PSMA PET/CT on oncologic outcomes of patients with recurrent prostate cancer: the experience of 3 high-volume european centers. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01277-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
15
|
Cucchiara V, Mazzone E, Robesti D, Gandaglia G, Stabile A, Scuderi S, Leni R, Barletta F, Nocera L, Necchi A, Raggi D, Marandino L, Balestrazzi E, Fanti S, Farolfi A, Bianchi L, Schiavina R, Montorsi F, Briganti A. Optimizing timing and indications for 68Ga-PSMA PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01242-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
16
|
Cominotti R, Berti A, Farolfi A, Zenesini A, Lamporesi G, Carusotto I, Recati A, Ferrari G. Observation of Massless and Massive Collective Excitations with Faraday Patterns in a Two-Component Superfluid. Phys Rev Lett 2022; 128:210401. [PMID: 35687467 DOI: 10.1103/physrevlett.128.210401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Revised: 01/28/2022] [Accepted: 04/19/2022] [Indexed: 06/15/2023]
Abstract
We report on the experimental measurement of the dispersion relation of the density and spin collective excitation modes in an elongated two-component superfluid of ultracold bosonic atoms. Our parametric spectroscopic technique is based on the external modulation of the transverse confinement frequency, leading to the formation of density and spin Faraday waves. We show that the application of a coherent coupling between the two components reduces the phase symmetry and gives a finite mass to the spin modes.
Collapse
Affiliation(s)
- R Cominotti
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, and Trento Institute for Fundamental Physics and Applications, INFN, 38123 Povo, Italy
| | - A Berti
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, and Trento Institute for Fundamental Physics and Applications, INFN, 38123 Povo, Italy
| | - A Farolfi
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, and Trento Institute for Fundamental Physics and Applications, INFN, 38123 Povo, Italy
| | - A Zenesini
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, and Trento Institute for Fundamental Physics and Applications, INFN, 38123 Povo, Italy
| | - G Lamporesi
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, and Trento Institute for Fundamental Physics and Applications, INFN, 38123 Povo, Italy
| | - I Carusotto
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, and Trento Institute for Fundamental Physics and Applications, INFN, 38123 Povo, Italy
| | - A Recati
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, and Trento Institute for Fundamental Physics and Applications, INFN, 38123 Povo, Italy
| | - G Ferrari
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, and Trento Institute for Fundamental Physics and Applications, INFN, 38123 Povo, Italy
| |
Collapse
|
17
|
Robesti D, Mazzone E, Gandaglia G, Stabile A, Scuderi S, Barletta F, Nocera L, Leni R, Marandino L, Raggi D, Necchi A, Balestrazzi E, Fanti S, Farolfi A, Bianchi L, Schiavina R, Montorsi F, Briganti A. Optimizing timing and indications for 68Ga-PSMA PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00277-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
18
|
Mazzone E, Robesti D, Gandaglia G, Stabile A, Cucchiara V, Bravi C, Necchi A, Raggi D, Marandino L, Cirulli G, Balestrazzi E, Fanti S, Cucchiara V, Farolfi A, Bianchi L, Schiavina R, Montorsi F, Briganti A. Can pelvic lymph node dissection be omitted at the time of radical prostatectomy in patients with a negative preoperative 68Ga-PSMA PET/CT? The importance of patient risk stratification according to individual risk of lymph node metastases. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00742-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Droghetti M, Bianchi L, Costa F, Balestrazzi E, Chessa F, Ceci F, Mei R, Farolfi A, Castellucci P, Piazza P, Puliatti S, Larcher A, Gandaglia G, Mottrie A, Briganti A, Fanti S, Montorsi F, Schiavina R, Brunocilla E. Oncological outcomes in patients with recurrent prostate cancer staged with PSMA PET/CT: Results from 3 European tertiary centers. Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00276-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Zamboglou C, Schmidt-Hegemann N, Emmett L, Strouthos I, Ferentinos K, Serani F, Farolfi A, Fanti S, Federica M, Lanzafame H, Kirste S, Ruf J, Vrachimis A, Ceci F, Grosu A, Henkenberens C. Metastasis-free survival after salvage radiotherapy for post-operative prostate cancer patients in the PSMA PET/CT era – a multicenter analysis. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)03122-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
21
|
Bianchi L, Mattana F, Balesrtazzi E, Farolfi A, Angiolini A, Droghetti M, Ercolino A, Farneti F, Morganti A, Briganti A, Montorsi F, Schiavina R, Brunocilla E, Castellucci P, Fanti S. 68Ga PSMA PET/CT for staging high risk prostate cancer patients suitable for radical treatments: Effective clinic implication and preliminary diagnostic performance. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)03090-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
22
|
Bianchi L, Ceci F, Droghetti M, Castellucci P, Artigas C, Leite J, Corona P, Farolfi A, Shagera Q, Moreira R, Gonzales C, Queiroz M, Barbosa F, Schiavina R, Brunocilla E, Deandreis D, Fanti S. External validation of a nomogram for predicting 68GA-PSMA PET/CT detection rate in patients with prostate cancer recurrence: a clinical tool to guide physicians before suggesting 68GA-PSMA PET/CT. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)00968-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
23
|
Conteduca V, Scarpi E, Wetterskog D, Brighi N, Schepisi G, Romanel A, Casadei C, Lolli C, Gurioli G, Toma I, Poti G, Farolfi A, Demichelis F, Attard G, De Giorgi U. 583P Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
24
|
Giannone G, Scotto G, Katsaros D, De Giorgi U, Farolfi A, Borella F, Cosma S, Ferrero A, Mangiacotti S, Villa M, Tuninetti V, Ghisoni E, Turinetto M, Mittica G, Gemmiti S, Zavallone L, Aglietta M, Pasini B, Di Maio M, Valabrega G. Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. Gynecol Oncol 2021; 162:80-87. [PMID: 33896588 DOI: 10.1016/j.ygyno.2021.04.018] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Accepted: 04/13/2021] [Indexed: 02/06/2023]
Abstract
BACKGROUND Hypersensitivity reactions (HSRs) to platinum are an important issue in the treatment of patients (pts) with ovarian cancer (OC). Germline BRCA mutations have been proposed as a risk factor. We aimed at evaluating the incidence and severity of HSRs to platinum in OC pts. with known BRCA status. PATIENTS AND METHODS We retrospectively analyzed 432 pts. from 5 Italian Centers. In addition, we performed a systematic review and meta-analysis of published series. RESULTS Four hundred nine pts. received at least one prior platinum-based treatment line: 314 were BRCA wild type (77%) and 95 were BRCA mutated (23%). There was no statistical difference in exposure to platinum. Incidence of any grade HSRs was higher among BRCA mutated pts. [9% vs 18%, p = 0.019] and the time-to-HSRs curves show that the risk increases with the duration of platinum exposure, in BRCA mutated pts. more than in BRCA wild type. A multivariable analysis showed that harboring a germline BRCA mutation was related to a higher incidence of HSRs (HR: 1.84, 95% CI 1.00-3.99, p = 0.05) while having received pegylated liposomal doxorubicin (PLD) was related to a lower incidence of HSRs (HR: 0.03 95% CI 0.004-0.22, p = 0.001). The systematic review confirmed the higher incidence of HSRs in BRCA mutated pts., though heterogeneity among series was significant. CONCLUSIONS In OC pts. with BRCA mutations, there is a significantly higher incidence of HSRs to carboplatin, not justified by longer drug exposure. On the other hand, PLD exerted a protective role in our series.
Collapse
Affiliation(s)
- G Giannone
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy; Department of Oncology, University of Turin, Turin, Italy.
| | - G Scotto
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy; Department of Oncology, University of Turin, Turin, Italy
| | - D Katsaros
- Department of Surgical Science and Gynecology, Azienda Ospedaliero Universitaria, Città della Salute, presidio S. Anna, University of Turin, Turin, Italy
| | - U De Giorgi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - A Farolfi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - F Borella
- Department of Surgical Science and Gynecology, Azienda Ospedaliero Universitaria, Città della Salute, presidio S. Anna, University of Turin, Turin, Italy
| | - S Cosma
- Department of Surgical Science and Gynecology, Azienda Ospedaliero Universitaria, Città della Salute, presidio S. Anna, University of Turin, Turin, Italy
| | - A Ferrero
- Academic Department Gynaecology and Obstetrics, University of Turin, A.O. Ordine Mauriziano, Turin, Italy
| | | | - M Villa
- Academic Department Gynaecology and Obstetrics, University of Turin, A.O. Ordine Mauriziano, Turin, Italy
| | - V Tuninetti
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy; Department of Oncology, University of Turin, Turin, Italy
| | - E Ghisoni
- Department of Oncology, Lausanne University Hospital, Switzerland; Ludwig Institute for Cancer Research, Lausanne, Switzerland
| | - M Turinetto
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy; Department of Oncology, University of Turin, Turin, Italy
| | - G Mittica
- Unit of Oncology, ASL Verbano Cusio Ossola (VCO), Omegna (VB), Italy
| | - S Gemmiti
- Department of Surgical Science and Gynecology, Azienda Ospedaliero Universitaria, Città della Salute, presidio S. Anna, University of Turin, Turin, Italy
| | - L Zavallone
- Department of Medical Oncology, Infermi Hospital, Biella, Italy
| | - M Aglietta
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy; Department of Oncology, University of Turin, Turin, Italy
| | - B Pasini
- Department of Medical Sciences, University of Turin, Turin, Italy
| | - M Di Maio
- Department of Oncology, A.O. Ordine Mauriziano Hospital, University of Turin, Turin, Italy
| | - G Valabrega
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy; Department of Oncology, University of Turin, Turin, Italy
| |
Collapse
|
25
|
Mordini C, Trypogeorgos D, Farolfi A, Wolswijk L, Stringari S, Lamporesi G, Ferrari G. Measurement of the Canonical Equation of State of a Weakly Interacting 3D Bose Gas. Phys Rev Lett 2020; 125:150404. [PMID: 33095638 DOI: 10.1103/physrevlett.125.150404] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 09/08/2020] [Indexed: 06/11/2023]
Abstract
Using a multiple-image reconstruction method applied to a harmonically trapped Bose gas, we determine the equation of state of uniform matter across the critical transition point, within the local density approximation. Our experimental results provide the canonical description of pressure as a function of the specific volume, emphasizing the dramatic deviations from the ideal Bose gas behavior caused by interactions. They also provide clear evidence for the nonmonotonic behavior with temperature of the chemical potential, which is a consequence of superfluidity and Bose-Einstein condensation. The measured thermodynamic quantities are compared to mean-field predictions available for the interacting Bose gas. The limits of applicability of the local density approximation near the critical point are also discussed, focusing on the behavior of the isothermal compressibility.
Collapse
Affiliation(s)
- C Mordini
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, Povo 38123, Italy,‡
| | - D Trypogeorgos
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, Povo 38123, Italy,‡
- Trento Institute for Fundamental Physics and Applications, INFN, Povo 38123, Italy
| | - A Farolfi
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, Povo 38123, Italy,‡
- Trento Institute for Fundamental Physics and Applications, INFN, Povo 38123, Italy
| | - L Wolswijk
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, Povo 38123, Italy,‡
- Trento Institute for Fundamental Physics and Applications, INFN, Povo 38123, Italy
| | - S Stringari
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, Povo 38123, Italy,‡
| | - G Lamporesi
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, Povo 38123, Italy,‡
- Trento Institute for Fundamental Physics and Applications, INFN, Povo 38123, Italy
| | - G Ferrari
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, Povo 38123, Italy,‡
- Trento Institute for Fundamental Physics and Applications, INFN, Povo 38123, Italy
| |
Collapse
|
26
|
Farolfi A, Trypogeorgos D, Mordini C, Lamporesi G, Ferrari G. Observation of Magnetic Solitons in Two-Component Bose-Einstein Condensates. Phys Rev Lett 2020; 125:030401. [PMID: 32745386 DOI: 10.1103/physrevlett.125.030401] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2019] [Revised: 02/11/2020] [Accepted: 06/11/2020] [Indexed: 06/11/2023]
Abstract
We experimentally investigate the dynamics of spin solitary waves (magnetic solitons) in a harmonically trapped, binary superfluid mixture. We measure the in situ density of each pseudospin component and their relative local phase via an interferometric technique we developed and as such, fully characterize the magnetic solitons while they undergo oscillatory motion in the trap. Magnetic solitons exhibit nondispersive, dissipationless longtime dynamics. By imprinting multiple magnetic solitons in our ultracold gas sample, we engineer binary collisions between solitons of either the same or opposite magnetization and map out their trajectories.
Collapse
Affiliation(s)
- A Farolfi
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, and Trento Institute for Fundamental Physics and Applications, INFN, 38123 Povo, Italy
| | - D Trypogeorgos
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, and Trento Institute for Fundamental Physics and Applications, INFN, 38123 Povo, Italy
| | - C Mordini
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, and Trento Institute for Fundamental Physics and Applications, INFN, 38123 Povo, Italy
| | - G Lamporesi
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, and Trento Institute for Fundamental Physics and Applications, INFN, 38123 Povo, Italy
| | - G Ferrari
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, and Trento Institute for Fundamental Physics and Applications, INFN, 38123 Povo, Italy
| |
Collapse
|
27
|
Piatti G, De Santi MM, Farolfi A, Zuccotti GV, D’Auria E, Patria MF, Torretta S, Consonni D, Ambrosetti U. Exacerbations and Pseudomonas aeruginosa colonization are associated with altered lung structure and function in primary ciliary dyskinesia. BMC Pediatr 2020; 20:158. [PMID: 32284045 PMCID: PMC7153224 DOI: 10.1186/s12887-020-02062-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Accepted: 03/31/2020] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Recurrent bacterial infections of the respiratory tract are one of the major clinical features of the primary ciliary dyskinesia (PCD), a rare genetic disease due to malfunctioning of motile cilia. Chronic infections and persistent inflammation of the respiratory system result in progressive lung disease. Aim of the study was to highlight the main factors associated with clinical, functional and anatomical deterioration in PCD patients. METHODS We retrospectively analyzed data from 58 patients with PCD, 37 adults and 21 children. The demographic and clinical data, forced expiratory volume at 1 s (FEV1) and forced vital capacity (FVC), sputum microbiology and imaging results (chest CT scores-modified Bhalla) were recorded. Patients were stratified according to the number of exacerbations (< 2/year vs ≥ 2/year) and chronic Pseudomonas aeruginosa (PA) colonization. The possible correlations between lung function and chest CT scores were assessed; we also evaluated the correlation between these parameters and the severity scores for bronchiectasis (BSI, FACED and e-FACED). RESULTS Chest CT scores showed a significant correlation with FEV1 (p = 0.0002), age (p < 0.0001), BMI (p = 0.0002) and number of lung lobes involved (p < 0.0001). PA colonization had an overall prevalence of 32.6%: no significant difference in FEV1 between PA colonized and non-colonized patients was found (p = 0.70), while chest CT score was significantly worse in chronic PA colonized patients (p = 0.009). Patients with a high number of exacerbation (≥ 2/year) were older (p = 0.01), had lower FEV1 (p = 0.03), greater number of lobes involved (p < 0.001) and worse CT score than patients with low number of exacerbations (p = 0.001); they also had higher prevalence of PA chronic bronchial infection (33.3% versus 13.6%, p = 0.10). Multivariable linear regression analyses adjusted for gender, age and BMI showed positive associations between PA colonization and number of exacerbations with severity of disease (number of lobes involved, CT score, BSI, FACED, and e-FACED). CONCLUSIONS In our PCD population the number of exacerbations (≥ 2/year) and PA colonization were the two most relevant factors associated with severity of disease.
Collapse
Affiliation(s)
- G. Piatti
- Department of Pathophysiology and Transplantation, University of Milan and Unit of Bronchopneumology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35 -, 20122 Milan, Italy
| | - M. M. De Santi
- Department of Human Pathology and Oncology, University of Siena and Unit of Pathological Anatomy, Policlinico Le Scotte, Strada delle Scotte 6, Siena, Italy
| | - A. Farolfi
- Pediatric Pulmonology, Pediatric Department, Vittore Buzzi Children’s Hospital, University of Milan, via Castelvetro 32, 20154 Milan, Italy
| | - G. V. Zuccotti
- Pediatric Pulmonology, Pediatric Department, Vittore Buzzi Children’s Hospital, University of Milan, via Castelvetro 32, 20154 Milan, Italy
| | - E. D’Auria
- Pediatric Pulmonology, Pediatric Department, Vittore Buzzi Children’s Hospital, University of Milan, via Castelvetro 32, 20154 Milan, Italy
| | - M. F. Patria
- Department of Pathophysiology and Transplantation, University of Milan and Paediatric Highly Intensive Care Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35 Milan, Italy
| | - S. Torretta
- Department of Clinical Sciences and Community Health, University of Milan and Division of Otolaryngology, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, Milan, Italy
| | - D. Consonni
- Epidemiology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35 Milan, Italy
| | - U. Ambrosetti
- Department of Clinical Sciences and Community Health, University of Milan and Audiology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35 Milan, Italy
| |
Collapse
|
28
|
Sánchez-Izquierdo N, Calderoni L, Farolfi A, Paredes P, Fuster D, Castellucci P. 11C-Choline PET/CT detects multiple small peritoneal metastasis in a prostate cancer patient. Rev Esp Med Nucl Imagen Mol 2019; 39:104-105. [PMID: 31810773 DOI: 10.1016/j.remn.2019.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Revised: 07/26/2019] [Accepted: 08/27/2019] [Indexed: 11/17/2022]
Affiliation(s)
| | - L Calderoni
- Department of Nuclear Medicine, University of Bologna, S. Orsola-Malpighi University Hospital, Bolonia, Italia
| | - A Farolfi
- Department of Nuclear Medicine, University of Bologna, S. Orsola-Malpighi University Hospital, Bolonia, Italia
| | - P Paredes
- Departamento de Medicina Nuclear, Hospital Clínic, Barcelona, España
| | - D Fuster
- Departamento de Medicina Nuclear, Hospital Clínic, Barcelona, España
| | - P Castellucci
- Department of Nuclear Medicine, University of Bologna, S. Orsola-Malpighi University Hospital, Bolonia, Italia
| |
Collapse
|
29
|
Farolfi A, Trypogeorgos D, Colzi G, Fava E, Lamporesi G, Ferrari G. Design and characterization of a compact magnetic shield for ultracold atomic gas experiments. Rev Sci Instrum 2019; 90:115114. [PMID: 31779406 DOI: 10.1063/1.5119915] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/14/2019] [Accepted: 10/04/2019] [Indexed: 06/10/2023]
Abstract
We report on the design, construction, and performance of a compact magnetic shield that facilitates a controlled, low-noise environment for experiments with ultracold atomic gases. The shield was designed to passively attenuate external slowly varying magnetic fields while allowing for ample optical access. The geometry, number of layers, and choice of materials were optimized using extensive finite-element numerical simulations. The measured performance of the shield is in good agreement with the simulations. From measurements of the spin coherence of an ultracold atomic ensemble, we demonstrate a residual field noise of 2.6 μG and a suppression of external dc magnetic fields by more than five orders of magnitude.
Collapse
Affiliation(s)
- A Farolfi
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, 38123 Povo, Italy
| | - D Trypogeorgos
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, 38123 Povo, Italy
| | - G Colzi
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, 38123 Povo, Italy
| | - E Fava
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, 38123 Povo, Italy
| | - G Lamporesi
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, 38123 Povo, Italy
| | - G Ferrari
- INO-CNR BEC Center and Dipartimento di Fisica, Università di Trento, 38123 Povo, Italy
| |
Collapse
|
30
|
Farolfi A, Scarpi E, Greco F, Bergamini A, Longo L, Pignata S, Casanova C, De Vecchio V, Bologna A, Orditura M, Zavallone L, Ventriglia J, Gallà V, Franzese E, Pigozzi E, Loizzi V, Giorda G, Giardina D, Cioffi R, De Giorgi U. Neutrophil-to-lymphocyte ratio predicts platinum sensitivity in epithelial ovarian cancer patients: A MITO24 retrospective study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Siepe G, Buwenge M, Capocaccia I, Farolfi A, Graziani T, Castellucci P, Ntreta M, Macchia G, Deodato F, Cilla S, Cammelli S, Frezza G, Fanti S, Morganti A. PV-0622: Impact and efficacy of 68GA-PSMA PET/CT in recurrent prostate cancer patients with PSA < 0.5 ng/ml. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30932-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Amadori D, Serra P, Bravaccini S, Farolfi A, Puccetti M, Carretta E, Medri L, Nanni O, Tumedei MM, Kahima J, Masalu N. Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations. Breast Cancer Res Treat 2014; 145:177-83. [PMID: 24658893 DOI: 10.1007/s10549-014-2903-0] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2013] [Accepted: 02/27/2014] [Indexed: 12/20/2022]
Abstract
Information on hormone receptor and human epidermal growth factor receptor-2 (HER2) expression in breast cancer is acknowledged as mandatory for prognostic stratification and treatment planning. Data on the biological features of African breast cancers are poor. We decided to compare histopathological and biomolecular characteristics (estrogen and progesterone receptor—ER, PgR, and HER2) of Tanzanian and Italian breast cancers. Differences in proliferating index and androgen receptor (AR) expression in triple-negative patients from the two case series were also assessed. Of the 103 consecutive patients seen at the Bugando Medical Center (Mwanza, Tanzania) from 2003 to 2010, who underwent biopsy or surgical resection of primary breast cancer, 69 patients had tissue samples that were evaluable for estrogen receptor (ER), progesterone receptor (PgR), and HER2. Histopathological assessment and biomolecular determinations were performed at the Cancer Institute of Romagna (IRST IRCCS, Meldola, Italy). Caucasian breast cancers were randomly extracted from an electronic database and matched (1:2 ratio) for year of diagnosis and age at diagnosis. Median age of both populations was 51 years (range 27–84). With respect to Caucasian tumors, Tanzanian breast cancers at diagnosis more frequently showed high histological grade (mainly grade 3) (P = 0.03), advanced clinical stage (III or IV) (P\0.001), ER negativity (52.2 %, P\0.001) and high proliferation (P = 0.0002). Triple-negative tumors were over-represented in Tanzanian women. AR was positive in 38.5 and 38 %of triple-negative Tanzanian and Italian breast cancers, respectively. Our results show that histopathological and biomolecular characteristics in Tanzanian and Italian breast cancers differ substantially. The high frequency of poorly differentiated, ER-negative, highly proliferating tumors, together with advanced stage at presentation, could be considered as the main prognostic factors linked to the high mortality rates for breast cancer in the African population.
Collapse
|
33
|
Passardi A, Farolfi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana A, Ruscelli S, Mucciarini C, Lorusso V, Ragazzini A, Amadori D. Impact of Pre-Treatment Lactate Dehydrogenase (Ldh) Levels on Prognosis and Bevacizumab Efficacy in Advanced Colorectal Cancer Patients. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.62] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Farolfi A, Scarpi E, Schirone A, Bravaccini S, Maltoni R, Cecconetto L, Sarti S, Serra P, Amadori D, Rocca A. Time to Initiation of Adjuvant Chemotherapy in Patients with Rapidly Proliferating Early Breast Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu327.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Farolfi A, Scarpi E, Passardi A, Tassinari D, Tamberi S, Cavanna L, Fontana A, Mucciarini C, Vertogen B, Valgiusti M, Gardini AC, Valtancoli M, Pini S, Frassineti G. Body Mass Index and Bevacizumab-Based Therapy in Advanced Colorectal Cancer Patients: Evaluation of Clinical Outcome. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Farolfi A, Ridolfi L, Guidoboni M, Milandri C, Calzolari F, Scarpi E, Amadori D, Ridolfi R. Liver Metastases from Melanoma: Hepatic Intra-Arterial Chemotherapy. A Retrospective Study. J Chemother 2013; 23:300-5. [DOI: 10.1179/joc.2011.23.5.300] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
37
|
Farolfi A, Ibrahim T, Scarpi E, Amadori D. Biology matters: the clinical impact of single-receptor discordance on breast cancer. Ann Oncol 2013; 24:851. [DOI: 10.1093/annonc/mdt005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
|
38
|
Pietri E, Medri L, Farolfi A, Sarti S, Maltoni R, Cecconetto L, Ibrahim T, Paioli A, Serra L, Amadori D, Rocca A. P1-12-17: Fluorescent In Situ Hybridization Evaluation of HER2 Status in Tumors with Chromosome 17 Polysomy. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-12-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: According to the American Society of Clinical Oncology-College of American Pathologists recommendations for HER2 testing, a positive fluorescent in situ hybridization (FISH) result is defined as >6 HER2 gene copies/nucleus (for test systems with no internal control probe [single-color]) or as HER2 gene/chromosome 17 centromere (CEP17) ratio > 2.2 (for systems with an internal control probe [dual-color]). Although an increase in CEP17 copy number (average ≥ 3.0 copies/nucleus) is commonly considered to represent polysomy of chromosome 17, it can also be a result of gains of 17q with centromere involvement, or amplification of the centromeric region. The classification of HER2−positive tumors according to the HER2/CEP17 ratio may therefore misclassify a fraction of truly amplified cases as polysomic. We prospectively evaluated tumors with chromosome 17 polysomy but no HER2 amplification to assess HER2 status using the above two FISH classifications and immunohistochemistry (IHC).
Materials and methods: Tumors were tested for gene amplification by FISH with probes to HER2/neu and CEP17 using the PathVysion HER-2 DNA Probe Kit (Vysis). Classification was based on the HER2/CEP17 ratio (amplified when > 2.2) and average HER2 gene copy number/nucleus (amplified when > 6 copies). Both polysomic and equivocal cases (HER2/CEP17 ratio 1.8 - 2.2) were further studied by IHC using the HercepTest (Dako) with 0–3 scoring system (overexpression when 3+).
Results: From March 2010 to May 2011 we evaluated 31 primary breast cancers showing chromosome 17 polysomy. Median HER2/CEP17 ratio was 1.3 (range 0.5−1.9), median HER2 copy number was 5.4 (range 2.6−13.8), and median CEP17 copy number was 4.2 (range 3.2−8.0). Thirteen (42%) had an average HER2 gene copy number > 6/nucleus (median 6.8, range 6.1−13.8) and would therefore be considered as amplified if classified according to the absolute HER2 gene copy number. Nine (75%) of these were 3+ at IHC and the remaining 4 were 2+, whereas among the 18 cases with an average HER2 gene copy number < 6/nucleus, one was 2+, ten were 1+, and 7 scored 0. Twenty-nine cases showed negative HER2/CEP17 ratios (< 1.8) and three cases equivocal HER2/CEP17 ratios (between 1.8 and 2.2). Using HER2/CEP17 ratio as first assessment and IHC only in equivocal cases, only one of the 31 “polysomic” cases would have been classified as HER2−positive. However, 8 polysomic cases with HER2/CEP17 ratio < 1.8 showed 3+ immunostaining (all with average HER2 gene copy number > 6/nucleus), while 3 other cases had an average HER2 gene copy number > 6/nucleus with 2+ immunostaining.
Conclusions: Our results show that both FISH evaluation criteria and IHC can modify the percentage of polysomic tumors classified as HER2−positive. However, the number of gene copies/nucleus appears more frequently associated with 3+ IHC than the HER2/CEP17 ratio. The predictive impact of the former method on response to anti-HER2 treatments warrants further investigation.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-12-17.
Collapse
Affiliation(s)
- E Pietri
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, (FC), Italy; Morgagni-Pierantoni Hospital, Forlì, (FC), Italy
| | - L Medri
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, (FC), Italy; Morgagni-Pierantoni Hospital, Forlì, (FC), Italy
| | - A Farolfi
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, (FC), Italy; Morgagni-Pierantoni Hospital, Forlì, (FC), Italy
| | - S Sarti
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, (FC), Italy; Morgagni-Pierantoni Hospital, Forlì, (FC), Italy
| | - R Maltoni
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, (FC), Italy; Morgagni-Pierantoni Hospital, Forlì, (FC), Italy
| | - L Cecconetto
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, (FC), Italy; Morgagni-Pierantoni Hospital, Forlì, (FC), Italy
| | - T Ibrahim
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, (FC), Italy; Morgagni-Pierantoni Hospital, Forlì, (FC), Italy
| | - A Paioli
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, (FC), Italy; Morgagni-Pierantoni Hospital, Forlì, (FC), Italy
| | - L Serra
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, (FC), Italy; Morgagni-Pierantoni Hospital, Forlì, (FC), Italy
| | - D Amadori
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, (FC), Italy; Morgagni-Pierantoni Hospital, Forlì, (FC), Italy
| | - A Rocca
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, (FC), Italy; Morgagni-Pierantoni Hospital, Forlì, (FC), Italy
| |
Collapse
|
39
|
Masalu N, Farolfi A, Serra P, Faustine L, Kopf B, Majinge CR, Amadori D. Intervention model for cancer control in a low-income African area. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e16539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Minervini MG, Priore P, Farolfi A, Cesana B, Morselli PL. Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients. Pharmacopsychiatry 1990; 23:102-6. [PMID: 1971117 DOI: 10.1055/s-2007-1014491] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
In this double-blind study, alpidem, a new imidazo-pyridine anxiolytic drug, was compared with placebo in order to test its efficacy and safety in chronic schizophrenic in-patients suffering from anxiety not directly related to the schizophrenic process. Sixty-six patients aged from 18 to 65 entered the trial. They also scored at least 18 on the Hamilton Rating Scale for Anxiety (HRSA) after a seven-day placebo run-in. Improvement in symptoms was evaluated by means of the HRSA, the Brief Psychiatric Rating Scale (BPRS), a Visual Analogue Scale (VAS), and the Clinical Global Impression score (CGI). Thirty-three patients were randomly allocated to alpidem and 33 to placebo. Alpidem was significantly more effective (P less than 0.0001) than placebo in improving HRSA scores (total score and factorial scores for somatic and psychic anxiety), BPRS, and VAS. Considering the results of CGI at 21 day, more patients were moderately to markedly improved on alpidem (30/33) than on placebo (2/33) (P less than 0.0001). The efficacy index, according to CGI, was significantly better (P less than 0.001 at least) for alpidem than for placebo. Side-effects were negligible in both groups.
Collapse
Affiliation(s)
- M G Minervini
- Department of Psychiatry Opera Don Uva Hospital, Bisceglie, Italy
| | | | | | | | | |
Collapse
|
41
|
Casacchia M, Farolfi A, Priore P, Magni G, Stratta P, Cesana B, Rossi A. A double-blind, placebo-controlled study of alpidem, a novel anxiolytic of imidazopyridine structure, in chronically anxious patients. Acta Psychiatr Scand 1989; 80:137-41. [PMID: 2572145 DOI: 10.1111/j.1600-0447.1989.tb01315.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
In this double-blind study alpidem, a new imidazopyridine anxiolytic drug, was compared with placebo to assess its efficacy and safety in severely anxious patients at the fixed dose of 150 mg/day (50 mg t.i.d.) for 3 weeks. Fifty-nine patients with a score of at least 18 on the Hamilton Rating Scale for Anxiety (HRSA) entered the trial after a 3- to 7-day placebo run-in period. Symptom improvement was evaluated with the HRSA, the State and Trait Anxiety Inventory (STAI-1 and STAI-2), a Visual Analogue Scale (VAS) and the Clinical Global Impression (CGI). Alpidem was more effective than placebo in improving mean HRSA (total score and factorial scores for somatic and psychic anxiety), STAI-1 and STAI-2 and VAS scores. The efficacy index of the CGI was better for alpidem than for placebo. Side effects were negligible in both groups. Alpidem appears to be a new interesting anxiolytic drug devoid of significant sedative effects on mental functions.
Collapse
Affiliation(s)
- M Casacchia
- Department of Psychiatry, Faculty of Medicine, L'Aquila University, Italy
| | | | | | | | | | | | | |
Collapse
|
42
|
Bassi S, Albizzati MG, Ferrarese C, Frattola L, Cesana B, Piolti R, Farolfi A. Alpidem, a novel anxiolytic drug. A double-blind, placebo-controlled study in anxious outpatients. Clin Neuropharmacol 1989; 12:67-74. [PMID: 2565767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The anxiolytic activity of alpidem (150 mg/day) and its effects on psychomotor performances were compared with placebo in 60 outpatients. The trial was a double-blind, parallel group, and the two treatments were administered orally in three divided doses for 3 weeks. Eighteen male and 42 female patients (mean age, 39.6 years) suffering from generalized anxiety or adjustment disorder with anxious mood of at least 1-month duration entered the trial at the end of a 1-week placebo run-in period designed to exclude early placebo responders. Efficacy was assessed with the Hamilton rating scale for anxiety (HRSA), the state-trait anxiety inventory (STAI x 1: anxiety as state), a visual analogue scale (VAS), and clinical global impression (CGI). Psychomotor performance was assessed by the digit symbol substitution test (DSST). Alpidem was significantly more effective than placebo in decreasing the severity of anxiety, both in the physician's judgment [total HRSA (p = 0.007), psychic symptoms (p = 0.0040), somatic symptoms (p = 0.0002)] and in the patients' evaluation [STAI x 1 (p = 0.0001) and VAS (p = 0.0003)]. Psychomotor performance was improved by both treatments; there was no difference between results with alpidem and placebo at the DSST (p = 0.2801), but the improvement was almost twofold on alpidem. Side effects were negligible with both treatments and the efficacy index, obtained from the CGI, was significantly better with alpidem than with placebo after day 7 (at least p less than 0.03).
Collapse
Affiliation(s)
- S Bassi
- Neurological Clinic, Bassini Hospital, Monza, Italy
| | | | | | | | | | | | | |
Collapse
|
43
|
Terzano MG, Parrino L, Fioriti G, Farolfi A, Orofiamma B, Sauvanet JP. [Cyclic alternating pattern. A new approach to the pharmacology of sleep disorders]. Neurophysiol Clin 1988; 18:447-57. [PMID: 3185464 DOI: 10.1016/s0987-7053(88)80055-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
The Cyclic Alternating Pattern (CAP) is an intrinsic component of normal NREM sleep. This periodic activity is organized in biphasic 40-sec cycles clustered in sequences. CAP sequences are functionally correlated to long lasting arousal instability. CAP is induced by endogenous stimuli (change in sleep stage, body movements) but it is considerably increased by exogenous impulses (noise). CAP rate (CAPR) is a novel polysomnographic variable that measures the amount of CAP during sleep, and it may be calculated for total sleep time and total NREM sleep. We demonstrated that all-night exposure to a 45 dB(A) white noise induced a significant CAPR increase, correlated with impaired sleep quality, even without changes in sleep architecture. We hypothesized that administration of an hypnotic should attenuate this CAPR rise. This hypothesis was verified in a double-blind placebo study, in which 12 healthy young adults received zolpidem, a new imidazopyridine hypnotic. During the noise perturbed nights, zolpidem clearly demonstrated a protective effect on CAPR (mainly during slow wave sleep) and on sleep quality. CAPR appears to be a sensitive indicator of sleep quality, and the cumulative distribution of CAPR throughout the night represents a new method to evaluate the effects of an hypnotic in sleep.
Collapse
Affiliation(s)
- M G Terzano
- Département de neurologie, Université de Parme, Italie
| | | | | | | | | | | |
Collapse
|
44
|
Terzano MG, Parrino L, Fioriti G, Farolfi A, Spaggiari MC, Anelli S, Arcelloni T. Variations of cyclic alternating pattern rate and homeostasis of sleep organization: a controlled study on the effects of white noise and zolpidem. Pharmacol Biochem Behav 1988; 29:827-9. [PMID: 3413207 DOI: 10.1016/0091-3057(88)90218-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The Cyclic Alternating Pattern (CAP) is a physiologic structure of normal non-REM (NREM) sleep, functionally correlated to long-lasting arousal instability. In 12 healthy volunteers, a continuous 45 dB (A) white noise induced no remarkable changes on the standard sleep parameters. However, compared to the baseline conditions, the acoustic perturbation determined a significant increase of the Cyclic Alternating Pattern Rate (CAPR), that measures the amount of CAP during sleep. Ten mg of zolpidem, a novel imidazopyridine hypnotic compound, did not modify the structure of unperturbed sleep, but induced a highly significant reduction of the increased values of CAP Rate due to white noise. The homeostatic function of CAP is stressed. CAPR appears to be a highly sensitive indicator of environmental modification during sleep.
Collapse
Affiliation(s)
- M G Terzano
- Sleep Disorders Centre, Department of Neurology, University of Parma, Italy
| | | | | | | | | | | | | |
Collapse
|
45
|
Cirignotta F, Mondini S, Zucconi M, Gerardi R, Farolfi A, Lugaresi E. Zolpidem-polysomnographic study of the effect of a new hypnotic drug in sleep apnea syndrome. Pharmacol Biochem Behav 1988; 29:807-9. [PMID: 3413202 DOI: 10.1016/0091-3057(88)90212-2] [Citation(s) in RCA: 60] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Clinical studies have shown that zolpidem, an original imidazopyridine derivative, induces and maintains sleep and does not have daytime side-effects. Polysomnography has revealed that this drug has several interesting qualities that benzodiazepines do not possess: stages 3-4 increase, stage 2 is unchanged or slightly reduced and no abnormal changes are detected on the EEG tracing. Like benzodiazepines, zolpidem slightly reduces REM sleep. The Multiple Sleep Latency Test confirmed that the drug does not cause daytime drowsiness. All the hypnotic drugs studied up to now worsen heavy snoring and obstructive sleep apnea syndrome. A controlled double blind cross-over trial assessed the effects of a single dose of zolpidem 20 mg on nocturnal breathing in patients with mild forms of sleep apnea syndrome. The results indicate that, at this dose, the drug does not overcome the existing contraindications to the use of hypnotics in this syndrome.
Collapse
Affiliation(s)
- F Cirignotta
- Institute of Neurology, University of Bologna, Italy
| | | | | | | | | | | |
Collapse
|
46
|
Portaleone D, Varenna R, Farolfi A, Ferrentino R, Di Leo M, Marcenaro R, Ranieri G, Rusinenti P, Seidita F, Signori S. [Long-term development of chronic hepatitis caused by virus B in childhood]. Pediatr Med Chir 1984; 6:659-62. [PMID: 6535128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Ten children with chronic hepatitis B have been followed for at least 3 years. All patients received 2 liver biopsies, the first after 1 year of continuous liver disfunction and HBsAg positivity, and the second 2 years after, that showed a mild improvement of the histologic lesions in 4 cases of chronic persistent hepatitis (CPH) and in 1 case of chronic lobular hepatitis (CLH). Three children out of 5 with chronic active hepatitis (CAN) changed to CPH and the other 2 remained unchanged without any evidence of cirrhosis. No patient received any drug for the treatment of hepatitis.
Collapse
|
47
|
Carnelli V, Ronco G, Farolfi A, Simoni L, Siccardo L, Biella CA, Giulotto P. [Chronic lead poisoning in childhood: clinical experience]. Pediatr Med Chir 1984; 6:377-82. [PMID: 6442768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Since 1978, 818 children living near an industrial source of pollution have been screened for lead poisoning. Biochemical evidences of increased lead absorption have been found in 114 cases and in 62 of them it was of such degree to guarantee further investigations. Those 62 children received a thorough neuropsychologic evaluation revealing a significant reduction of IQ, learning difficulties, poor concentration and behavioral abnormalities. We also documented an increased rate of abnormal mathafases and breaks of chromatides in children with increased lead absorption compared with age and sex matched controls.
Collapse
|
48
|
Farolfi A, Cattaneo M, Varenna R, Portaleone D, Ferrentino R, Carnelli V. [Biliary atresia: pathogenetic considerations emerging from the histopathologic analysis of the liver parenchyma]. Pediatr Med Chir 1983; 5:69-73. [PMID: 6647066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Nine patients had been surgically treated for extrahepatic biliary atresia from 1974 to 1982. The analysis of the hepatic specimens obtained during the surgical exploration revealed a wide spectrum of histopathologic lesions. In 3 patients we found severe Giant-cell transformation, while in the other 6 it was not possible to ascribe the histopathologic picture to a univocal pathogenesis. Comparing our results to the reports of other Authors we believe biliary atresia can not be explained by a single pathologic mechanism. The obstruction of the extrahepatic bile ducts might be the common morphologic denominator of different pathologic entities, from each of them it depends a different evolution of the hepatic lesions and a different survival after Kasai's operation.
Collapse
|
49
|
Cavallotti C, Amenta F, Beatrice F, Farolfi A. [Neurotrophic effect of various nerve-tissue subfractions on denervated muscles]. Boll Soc Ital Biol Sper 1976; 52:1234-8. [PMID: 1023938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|